FDA Approves First Gene Therapy for Severe Leukocyte Adhesion Deficiency Type I
http://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapy-severe-leukocyte-adhesion-deficiency-type-i

FDA Approves Drug to Treat Neurologic Manifestations of Hunter Syndrome
http://www.fda.gov/news-events/press-announcements/fda-approves-drug-treat-neurologic-manifestations-hunter-syndrome

http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/cryoprobe-recall-erbe-usa-removes-flexible-cryoprobes

http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/heating-pad-recall-navajo-manufacturing-company-removes-handy-solutions-neck-shoulders-heating-pad

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/amneal-pharmaceuticals-llc-issues-voluntary-nationwide-recall-magnesium-sulfate-water-injection-usp

FDA Schedules Public Meeting on the Commissioner’s National Priority Voucher Pilot Program
http://www.fda.gov/news-events/press-announcements/fda-schedules-public-meeting-commissioners-national-priority-voucher-pilot-program

http://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/cardinal-health-issues-voluntary-nationwide-recall-webcoltm-large-alcohol-prep-pad

FDA Approves Fourth Product Under National Priority Voucher Program, Higher Dose Semaglutide
http://www.fda.gov/news-events/press-announcements/fda-approves-fourth-product-under-national-priority-voucher-program-higher-dose-semaglutide

FDA Releases Draft Guidance on Alternatives to Animal Testing in Drug Development
http://www.fda.gov/news-events/press-announcements/fda-releases-draft-guidance-alternatives-animal-testing-drug-development

http://www.fda.gov/medical-devices/medical-device-recalls-and-early-alerts/early-alert-surgical-stapler-issue-intuitive-surgical